ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
108,123.46
4.86%
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs Yen
156.369
0.03%
Brent Oil
79.72
-0.62%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Arbutus Biopharma Corporation (ABUS) 銘柄情報

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

NASDAQ
3.20
-0.02
(-0.62%)
終了 1月20日 6:00AM
15分遅延
3.25
0.05
(1.56%)
取引時間後: 9:37AM
15分遅延

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

主要統計と詳細

通貨
3.25
買値
3.11
売値
4.24
出来高
610,726
3.17 日の範囲 3.24
2.21 52 週間の範囲 4.725
時価総額
615.848M
前日終値
3.22
始値
3.23
時刻
3
@
3.33
最終取引時間
財務取引量
US$ 1,959,610
VWAP
3.2087
平均取引量 (3 か月)
844,335
発行済株式数
189,491,685
配当利回り
-
PER
-8.30
1 株当たり利益 (EPS)
-0.38
歳入
18.14M
純利益
-72.85M

Arbutus Biopharma Corporation について

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.tekmirapharm.com
本社
Burnaby, British Columbia, Can
設立
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ABUS. The last closing price for Arbutus Biopharma was US$3.22. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 2.21 to US$ 4.725.

Arbutus Biopharma currently has 189,491,685 shares in issue. The market capitalisation of Arbutus Biopharma is US$610.16 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.30.

Arbutus Biopharma (ABUS) のオプションフロー概要

オプションフロー全体を表示

全体の流れ

ブルリッシュ

ネットプレミアム

101k

Calls / Puts

200.00%

買い / 売り

100.00%

OTM / ITM

50.00%

Sweeps比率

0.00%

ABUS 最新ニュース

その他のニュース

Form 8-K - Current report

2025年1月13日
Edgar (US Regulatory)

Arbutus Provides 2025 Corporate and Financial Update

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025...

2025年1月13日
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

2024年12月6日
Edgar (US Regulatory)

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No...

2024年12月3日
Business Wire

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

2024年11月26日
GlobeNewswire Inc.

Form 8-K - Current report

2024年11月16日
Edgar (US Regulatory)

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...

2024年11月16日
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

2024年11月14日
Edgar (US Regulatory)

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

2024年11月14日
GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933

2024年11月7日
Edgar (US Regulatory)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.02-0.6116207951073.273.383.138147813.27116784CS
40.072.201257861643.183.543.119253503.26565738CS
12-0.8-19.75308641984.054.13.118443353.50467832CS
26-0.55-14.47368421053.84.7253.119772693.81505976CS
521.0145.08928571432.244.7252.2110775503.33725833CS
156-0.01-0.3067484662583.264.7251.6910380622.84530737CS
2600.185.863192182413.0790.8821409243.7186765CS

ABUS - Frequently Asked Questions (FAQ)

What is the current Arbutus Biopharma share price?
The current share price of Arbutus Biopharma is US$ 3.25
How many Arbutus Biopharma shares are in issue?
Arbutus Biopharma has 189,491,685 shares in issue
What is the market cap of Arbutus Biopharma?
The market capitalisation of Arbutus Biopharma is USD 610.16M
What is the 1 year trading range for Arbutus Biopharma share price?
Arbutus Biopharma has traded in the range of US$ 2.21 to US$ 4.725 during the past year
What is the PE ratio of Arbutus Biopharma?
The price to earnings ratio of Arbutus Biopharma is -8.3
What is the cash to sales ratio of Arbutus Biopharma?
The cash to sales ratio of Arbutus Biopharma is 33.33
What is the reporting currency for Arbutus Biopharma?
Arbutus Biopharma reports financial results in USD
What is the latest annual turnover for Arbutus Biopharma?
The latest annual turnover of Arbutus Biopharma is USD 18.14M
What is the latest annual profit for Arbutus Biopharma?
The latest annual profit of Arbutus Biopharma is USD -72.85M
What is the registered address of Arbutus Biopharma?
The registered address for Arbutus Biopharma is 100, 8900 GLENLYON PARKWAY, GLENLYON BUSINESS PARK, BURNABY, BRITISH COLUMBIA, V5J 5J8
What is the Arbutus Biopharma website address?
The website address for Arbutus Biopharma is www.tekmirapharm.com
Which industry sector does Arbutus Biopharma operate in?
Arbutus Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

ABUS Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
ABUS
Arbutus Biopharma
CSE
RAD
Radial Research
TG
AH8X
Allianz Global Investors
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有